Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2018

  • ID: 4576083
  • Report
  • 188 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acucela Inc
  • Astellas Pharma Inc
  • GenSight Biologics SA
  • InFlectis BioScience
  • Miragen Therapeutics Inc
  • Novartis AG
  • MORE
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2018, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

Report Highlights:

This latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 12, 3, 31 and 7 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 11 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acucela Inc
  • Astellas Pharma Inc
  • GenSight Biologics SA
  • InFlectis BioScience
  • Miragen Therapeutics Inc
  • Novartis AG
  • MORE
Introduction

Retinitis Pigmentosa (Retinitis) - Overview

Retinitis Pigmentosa (Retinitis) - Therapeutics Development

Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment

Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development

Retinitis Pigmentosa (Retinitis) - Drug Profiles

Retinitis Pigmentosa (Retinitis) - Dormant Projects

Retinitis Pigmentosa (Retinitis) - Discontinued Products

Retinitis Pigmentosa (Retinitis) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by EyePoint Pharmaceuticals Inc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Eyevensys SAS, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional SA, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Horama SA, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co Ltd, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by M's Science Corp, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by MimeTech Srl, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Miragen Therapeutics Inc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector srl, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Novartis AG, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Novelion Therapeutics Inc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Profarma, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by ProQR Therapeutics NV, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Recursion Pharmaceuticals Inc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio Inc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics Inc, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2018

Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2018 (Contd..1), H1 2018

Retinitis Pigmentosa (Retinitis) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acucela Inc
  • Allergan Plc
  • Amarantus Bioscience Holdings Inc
  • Amgen Inc
  • Applied Genetic Technologies Corp
  • Astellas Pharma Inc
  • Dompe Farmaceutici SpA
  • EyePoint Pharmaceuticals Inc
  • Eyevensys SAS
  • GenSight Biologics SA
  • Grupo Ferrer Internacional SA
  • Horama SA
  • ID Pharma Co Ltd
  • InFlectis BioScience
  • Ionis Pharmaceuticals Inc
  • M's Science Corp
  • MimeTech Srl
  • Miragen Therapeutics Inc
  • Nanovector srl
  • Novartis AG
  • Novelion Therapeutics Inc
  • Profarma
  • ProQR Therapeutics NV
  • Recursion Pharmaceuticals Inc
  • ReNeuron Group Plc
  • SanBio Inc
  • Sanofi
  • Spark Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll